Long-term follow-up for breast cancer trial participants
Part of Cancer, Skin clinical trials.
This follow-up study is for people who took part in earlier breast cancer gene tests (TAILORx or RxPONDER). It collects health information and tumor tissue over time to learn more about how breast cancer behaves after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been a participant in one of two earlier breast cancer trials: TAILORx or RxPONDER.
- If you were in TAILORx (any risk score) or RxPONDER (risk score 0–25), you must have had a biopsy-confirmed return of cancer (in the breast, nearby lymph nodes, or elsewhere).
- If you were in RxPONDER's first step and had a high risk score (26–100), you can join without a recurrence.
- You need to have a sample of your tumor tissue (from the original tumor or from the recurrence) available for research.
- You must be willing to sign a consent form to participate in this follow-up study. If you have a legally authorized representative, that is acceptable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
This study looks at a patient-led follow-up approach after early breast cancer treatment, where you may have more control and flexibility instead of routine hospital visits, while still on hormone therapy.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.